Certara (NASDAQ:CERT) Rating Lowered to Hold at Craig Hallum

Certara (NASDAQ:CERT) was downgraded by investment analysts at Craig Hallum from a “buy” rating to a “hold” rating in a report released on Friday, Marketbeat reports. They currently have a $10.00 price objective on the stock. Craig Hallum’s price target would suggest a potential upside of 41.24% from the stock’s previous close.

Several other research analysts have also issued reports on CERT. KeyCorp decreased their price target on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, January 8th. Stephens cut their price objective on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Friday, December 12th. Leerink Partners restated an “outperform” rating and issued a $10.00 target price on shares of Certara in a report on Thursday. Barclays cut their target price on Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.10.

Certara Trading Up 4.1%

Shares of CERT stock opened at $7.08 on Friday. The stock has a 50-day simple moving average of $8.36 and a 200 day simple moving average of $9.89. The stock has a market capitalization of $1.13 billion, a P/E ratio of -708.00 and a beta of 1.47. Certara has a fifty-two week low of $6.04 and a fifty-two week high of $15.38. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.19%. The business had revenue of $103.65 million during the quarter, compared to analyst estimates of $103.23 million. During the same period in the previous year, the company posted $0.15 earnings per share. Certara’s revenue was up 3.2% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, sell-side analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of institutional investors have recently bought and sold shares of CERT. AQR Capital Management LLC acquired a new position in shares of Certara in the 1st quarter valued at about $259,000. Goldman Sachs Group Inc. increased its stake in Certara by 65.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock valued at $2,267,000 after buying an additional 90,724 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Certara by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock valued at $2,965,000 after buying an additional 35,954 shares during the period. Jane Street Group LLC lifted its position in Certara by 17.1% in the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after buying an additional 40,463 shares in the last quarter. Finally, Geneva Capital Management LLC boosted its stake in shares of Certara by 7.8% during the 2nd quarter. Geneva Capital Management LLC now owns 6,114,895 shares of the company’s stock valued at $71,544,000 after buying an additional 443,206 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

More Certara News

Here are the key news stories impacting Certara this week:

• Positive Sentiment: FY‑2025 results showed 9% revenue growth to $418.8M, adjusted EBITDA up 10% to $134.5M, and Q4 software revenue +10% — evidence of recovering commercial momentum in the higher‑margin software business. Certara Reports Fourth Quarter 2025 Financial Results
• Positive Sentiment: New CEO Jon Resnick is executing an operational overhaul with plans for sharper strategic focus and ~ $10M of cost avoidance — a management change investors often view as constructive for execution and long‑term growth. CEO signals operational overhaul
• Positive Sentiment: Barclays maintained an Overweight stance on CERT (despite lowering its price target), indicating some sell‑side support for the name even after recent guidance/earnings. Barclays price target change
• Neutral Sentiment: Management will participate in upcoming investor conferences — a chance to press the case for the turnaround and provide more color to investors. Investor conference participation
• Neutral Sentiment: Broker and media earnings breakdowns are circulating (useful for detail on items behind adjusted metrics and bookings vs. revenue). Earnings breakdown
• Negative Sentiment: GAAP and adjusted metrics disappointed in places: Q4 adjusted diluted EPS of $0.09 (down vs. prior year) and a GAAP net loss; management guided FY‑2026 revenue of only 0–4% (and set revenue range below Street expectations), which pressured near‑term growth expectations. Guidance and Q4 results
• Negative Sentiment: Craig Hallum downgraded CERT from Buy to Hold, reflecting analyst caution after the quarter and guidance; such downgrades can increase selling pressure. Analyst downgrade (Craig Hallum)

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.